Abstract
Antiviral T-cell immune responses appear to be crucial to control HIV replication. Infants treated before the third month of life with highly active antiretroviral treatment (HAART) did not develop a persistent HIV-specific immune response. We evaluated how delayed initiation of HAART after 3 months of age influences the development of HIV-1-specific T-cell responses during long-term follow-up in 9 HIV-1 vertically infected infants. These data suggest that a longer antigenic stimulation, due to a larger window for therapeutic intervention with HAART, is associated with the establishment of a persistent specific HIV immune response resulting in a long-term viral control of vertically infected infants.
MeSH terms
-
Amino Acid Sequence
-
Antiretroviral Therapy, Highly Active*
-
Drug Administration Schedule
-
HIV Infections / drug therapy*
-
HIV Infections / immunology*
-
HIV Infections / virology
-
HIV-1 / immunology*
-
Humans
-
Infant
-
Infectious Disease Transmission, Vertical*
-
Lymphocyte Activation
-
Molecular Sequence Data
-
Peptides / chemistry
-
T-Lymphocytes / immunology*
-
Treatment Outcome
-
gag Gene Products, Human Immunodeficiency Virus / chemistry
-
nef Gene Products, Human Immunodeficiency Virus / chemistry
-
tat Gene Products, Human Immunodeficiency Virus / chemistry
Substances
-
Peptides
-
gag Gene Products, Human Immunodeficiency Virus
-
nef Gene Products, Human Immunodeficiency Virus
-
tat Gene Products, Human Immunodeficiency Virus